Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/17/24 21:58 | 5/16/24 | GRTS | Health | BioPrd | Biological Products, (No Diag | Allen Andrew R | CA | DO | P,CEO | S.d | -18 | 0.7483 | 0 | -24 | -1 | 2,435 | D | ||||||||||||||
5/17/24 21:57 | 5/16/24 | GRTS | Health | BioPrd | Biological Products, (No Diag | Jones Erin | CA | O | EVP,COO | S.d | -10 | 0.7483 | 0 | -14 | -4 | 359 | D | ||||||||||||||
5/17/24 21:57 | 5/16/24 | GRTS | Health | BioPrd | Biological Products, (No Diag | Jooss Karin | CA | O | See Rema | S.d | -10 | 0.7483 | 0 | -14 | -2 | 684 | D | ||||||||||||||
5/17/24 21:56 | 5/16/24 | GRTS | Health | BioPrd | Biological Products, (No Diag | Hawryluk Matthew | CA | O | EVP,CHIE | S.d | -7 | 0.7483 | 0 | -9 | -3 | 314 | D | ||||||||||||||
5/17/24 21:55 | 5/16/24 | GRTS | Health | BioPrd | Biological Products, (No Diag | Economides Vassiliki | CA | O | EVP,CFO | S.d | -10 | 0.7483 | 0 | -14 | -5 | 262 | D | ||||||||||||||
5/24/23 17:24 | 5/23/23 | GRTS | Health | BioPrd | Biological Products, (No Diag | Economides Vassiliki | CA | O | See Rema | P | 23 | 1.90 | 0 | 12 | 6 | 214 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |